Premium
The challenge of defining “ultra‐high‐risk” neuroblastoma
Author(s) -
Morgenstern Daniel A.,
Bagatell Rochelle,
Cohn Susan L.,
Hogarty Michael D.,
Maris John M.,
Moreno Lucas,
Park Julie R.,
Pearson Andrew D.,
Schleiermacher Gudrun,
ValteauCouanet Dominique,
London Wendy B.,
Irwin Meredith S.
Publication year - 2019
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.27556
Subject(s) - risk stratification , medicine , neuroblastoma , stratification (seeds) , oncology , intensive care medicine , risk assessment , seed dormancy , genetics , germination , botany , computer security , dormancy , computer science , biology , cell culture
Given the biological and clinical heterogeneity of neuroblastoma, risk stratification is vital to determining appropriate treatment. Historically, most patients with high‐risk neuroblastoma (HR‐NBL) have been treated uniformly without further stratification. Attempts have been made to identify factors that can be used to risk stratify these patients and to characterize an “ultra‐high‐risk” (UHR) subpopulation with particularly poor outcome. However, among published data, there is a lack of consensus in the definition of the UHR population and heterogeneity in the endpoints and statistical methods used. This review summarizes our current understanding of stratification of HR‐NBL and discusses the complex issues in defining UHR neuroblastoma.